Patient experiences with pump-delivered Parkinson's drug
Part of Brain & nervous system clinical trials.
This study looks at real-world experiences of people with Parkinson's who are using ONAPGO, a medication given continuously under the skin through a pump. The goal is to understand how this treatment works in daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been prescribed ONAPGO (apomorphine pump) by your doctor.
- You agreed to receive support from a specially trained Parkinson's nurse.
- Your doctor thinks it is okay for you to be in this study.
- You are willing and able to sign a consent form to participate.
- You are not taking certain anti-nausea medications (like ondansetron or granisetron).
- You do not have a known allergy to apomorphine or sulfites (found in some foods and medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a continuous apomorphine pump can help people with advanced Parkinson's disease who can no longer take oral medications and are receiving palliative care. The pump delivers medicine under the skin to manage symptoms when other treatments are no longer possible.
This trial tests an experimental drug called AP-472, taken alongside your regular Parkinson's medications, to see if it can reduce the amount of "OFF" time you experience each day when symptoms return between doses of levodopa.
This study is looking at how a new continuous 24-hour injection treatment (foslevodopa/foscarbidopa) affects quality of life in people with advanced Parkinson's disease. It is a real-world study, meaning you just take the medication as your doctor prescribes, and researchers observe the results.
This study looks at how patients start and adjust a new medicine (sublingual apomorphine, or SL-APO) for Parkinson's disease OFF episodes. OFF episodes are times when Parkinson's symptoms come back between medicine doses. If you are about to start SL-APO for the first time, this trial may be a good fit.
This study tests a new formulation of carbidopa-levodopa (IPX-203) to see how well it works for people with Parkinson's disease. It uses a wearable device to measure movement and aims to improve “off” time, when symptoms return between doses.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.